CN1199958C - 获得用于头孢替坦生产的化合物的方法和由此获得的新化合物 - Google Patents
获得用于头孢替坦生产的化合物的方法和由此获得的新化合物 Download PDFInfo
- Publication number
- CN1199958C CN1199958C CNB021192413A CN02119241A CN1199958C CN 1199958 C CN1199958 C CN 1199958C CN B021192413 A CNB021192413 A CN B021192413A CN 02119241 A CN02119241 A CN 02119241A CN 1199958 C CN1199958 C CN 1199958C
- Authority
- CN
- China
- Prior art keywords
- isothiazole
- hydroxyl
- sulfydryl
- general formula
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- JTSGJBOQOHOUOT-UHFFFAOYSA-N 3-oxo-5-sulfanyl-1,2-thiazole-4-carboxylic acid Chemical class OC(=O)C=1C(O)=NSC=1S JTSGJBOQOHOUOT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000011734 sodium Substances 0.000 claims description 16
- 229910052700 potassium Inorganic materials 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 7
- XVYNCCCUYYIRAP-UHFFFAOYSA-N 3-oxo-5-sulfanyl-1,2-thiazole-4-carbonitrile Chemical compound OC1=NSC(S)=C1C#N XVYNCCCUYYIRAP-UHFFFAOYSA-N 0.000 claims description 6
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 5
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims description 5
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 abstract description 12
- 229960005495 cefotetan Drugs 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- FZEVMBJWXHDLDB-ZCFIWIBFSA-N (6r)-5-thia-1-azabicyclo[4.2.0]oct-2-en-8-one Chemical compound S1CC=CN2C(=O)C[C@H]21 FZEVMBJWXHDLDB-ZCFIWIBFSA-N 0.000 description 1
- -1 1-methyl tetrazolium-5-yl Chemical group 0.000 description 1
- VYVNHGBYOZFMMQ-UHFFFAOYSA-N 3-oxo-5-sulfanyl-1,2-thiazole-4-carboxylic acid;sodium Chemical compound [Na].[Na].[Na].OC(=O)C1=C(S)SNC1=O VYVNHGBYOZFMMQ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- NTYLEPQICJIWKK-UHFFFAOYSA-N SC1=CC=NS1 Chemical compound SC1=CC=NS1 NTYLEPQICJIWKK-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
Abstract
获得4-羧基-3-羟基-5-巯基-异噻唑的盐类的方法,该盐是用于头孢替坦生产的化合物,和由此获得的新化合物。
Description
发明领域
本发明涉及用于获得4-羧基-3-羟基-5-巯基-异噻唑的钠或钾盐的方法,该盐是用于头孢替坦生产的化合物,本发明还涉及由该方法获得的新化合物。
技术背景
头孢替坦是如下通式的半合成可注射头孢菌素:
根据在US-A-4263432中和在Chem.Pharm.Bull.28,2629-2636(1980)中描述的方法,头孢替坦从如下通式的7a-(4-羧基-3-羟基异噻唑-5-基)硫代乙酰氨基-7a-甲氧基-3-(1-甲基四唑-5-基)硫代甲基-A3-头孢烯(cephem)-4-羧酸获得的:
它自身是通过使7a-溴乙酰氨基-7a-甲氧基-3-(1-甲基四唑-5-基)硫代甲基-Δ3-头孢烯-4-羧酸与以下通式的4-羧基-3-羟基-5-巯基-异噻唑三钠反应而制备的:
其中R1=R2=R3=Na。
采用稀HCl将反应混合物调节到pH8.0并获得通式(I)化合物的沉淀物。通式(III)的4-羧基-3-羟基-5-巯基-异噻唑三钠(其中R1=R2=R3=Na)在头孢替坦的制备中是必要的中间体(根据已知技术)。
上述文献也描述了目前用于制备通式(III)的4-羧基-3-羟基-5-巯基-异噻唑三钠(其中R1=R2=R3=Na)的单一方法;此方法是冗长和不切合实际的,并且特别要求使用金属钠和液体氨,如在上述版本的Chem.Pharm.Bull.的2633页上详细解释的那样。
发明内容
因此,本发明的目的是提供用于制备通式(III)化合物的一种方法,该方法与已知方法比较在经济上是非常有利的,并且避免使用危险的物质如金属钠和氨。
因此本发明涉及一种获得如下通式的4-羧基-3-羟基-5-巯基-异噻唑盐类的方法
其中R1=R2=R3=Na或K;R1=Na或K并且R2=R3=H;或R1=R2=Na或K并且R3=H;其特征在于以3-6当量的量,将3-羟基-5-巯基-4-异噻唑腈的二钠或二钾盐在氢氧化钠或氢氧化钾的水溶液中回流至少15小地,分别得到含有4-羧基-3-羟基-5-巯基-异噻唑的三钠或三钾盐(III)的水溶液,其中R1=R2=R3=Na或K,当通过加入HCl将溶液pH修正到约8的最小值时,盐从此溶液中沉淀。
特别是将该水溶液的pH调节到8.0-8.5,以沉淀通式(III)化合物,其中R1=Na或K并且R2=R3=H。
通过使二氰基-1,1-亚乙基-二硫醇的二钠或二钾盐与30%过氧化氢反应,可以97%的收率容易地生产3-羟基-5-巯基-4-异噻唑腈的二钠或二钾盐,如在US-A-3230229中描述的那样。
其中R1=Na或K和R2=R3=H的通式(III)化合物的盐类是新化合物并且也形成本发明的目的。重要的是注意如果使用通式(III)化合物的三钠或三钾盐生产头孢替坦,必须通过大量加入浓HCl,而大大地降低此盐溶液(强碱溶液)的pH(至约pH8.5)。
本发明的单盐和二盐溶液也是碱性pH,但更低,以致这些溶液可以不需要加入HCl直接使用或仅加入最小量的HCl用于头孢替坦生产的直接工业用途。
最佳实施方式
为阐明对本发明特征的理解,以下给出一些非限制性实施例。
实施例1
通式(III)的化合物,其中R 1=Na并且R2 =R 3=H
将3-羟基-5-巯基-4-异噻唑腈的二钠盐(162.53g,0.8mol)溶于水(620ml)中,并将固体氢氧化钠(192g,4.8mol)加入到溶液中。
在回流下将溶液保持16小时并然后冷却到环境温度;以此方式,获得化合物(III)的水溶液(pH14),其中R1=R2=R3=Na。将水(380ml)加入到此溶液中,将温度降低到0℃,并通过加入浓HCl将pH修正到8.4。将混合物搅拌1小时,以获得沉淀物(由标题中所示化合物组成),将沉淀物过滤,以乙醇洗涤并在35℃减压下干燥8小时。
产量:157.4g白色粉末。
HPLC:80%;K.F.19.6%;m.p.160℃有分解。
13C-N.M.R.(DMSO-d6)(300MHz):188.94ppm;172.02ppm;171.26ppm;113.11ppm。
标题中所示化合物可溶于水,得到pH为约8.5的溶液。
实施例2
在用于头孢替坦合成的溶液中的通式(III)的化合物,其中R 1=Na并且R 2 =R 3=H
将3-羟基-5-巯基-4-异噻唑腈的二钠盐(86.7g,0.43mol)溶于水(180ml)中,并将固体氢氧化钠(51.5g,1.29mol)加入到溶液中。
在回流下将溶液保持16小时并然后冷却到环境温度。将水(380ml)加入到此溶液中,将温度降低到10℃,并通过加入浓HCl将pH修正到8.5。获得的溶液可直接用于制备头孢替坦。
实施例3
在用于头孢替坦合成的溶液中的通式(III)化合物,其中R 1=K并且R 2 =R 3=H
将3-羟基-5-巯基-4-异噻唑腈的二钾盐(62.5g,0.27mol)溶于水(238ml)中,并将固体氢氧化钾(90.9g,1.62mol)加入到溶液中。
在回流下将溶液保持18小时并然后冷却到环境温度,得到溶液,并通过加入浓HCl将该溶液的pH修正到8.5。将温度降低到10℃并且获得的溶液可直接用于制备头孢替坦。
Claims (2)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000964A/2001 | 2001-05-10 | ||
IT2001MI000964A ITMI20010964A1 (it) | 2001-05-10 | 2001-05-10 | Procedimento per l'ottenimento di composti utili per la produzione del cefotetan e nuovi composti cosi' ottenuti |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1385426A CN1385426A (zh) | 2002-12-18 |
CN1199958C true CN1199958C (zh) | 2005-05-04 |
Family
ID=11447631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021192413A Expired - Fee Related CN1199958C (zh) | 2001-05-10 | 2002-05-10 | 获得用于头孢替坦生产的化合物的方法和由此获得的新化合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US6583291B2 (zh) |
EP (1) | EP1258482A1 (zh) |
KR (1) | KR100858007B1 (zh) |
CN (1) | CN1199958C (zh) |
IT (1) | ITMI20010964A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100668424B1 (ko) * | 2005-02-04 | 2007-01-12 | 주식회사 메타바이오메드 | 치과용 무선 복합 근관 충전장치 |
ITMI20051085A1 (it) * | 2005-06-10 | 2006-12-11 | Acs Dobfar Spa | Metodo di purificazione del cefotetan |
ITMI20051115A1 (it) * | 2005-06-14 | 2006-12-15 | Acs Dobfar Spa | Procedimento per l'ottenimento di cefotetan con resa elevata |
KR101110331B1 (ko) * | 2010-04-01 | 2012-02-15 | 이창민 | 이소티아졸 유도체 및 그 제조방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3230229A (en) * | 1961-10-19 | 1966-01-18 | Du Pont | Selected isothiazoles and their preparation |
US3887352A (en) * | 1967-03-09 | 1975-06-03 | Rohm & Haas | Control of microorganisms with 3-hydroxyisothiazoles |
CH648317A5 (de) | 1977-06-10 | 1985-03-15 | Yamanouchi Pharma Co Ltd | 7alpha-methoxy-7betha-(1,3-dithietan-2- carboxamido)cephalosporansaeurederivate und verfahren zu ihrer herstellung. |
US4508908A (en) * | 1978-10-16 | 1985-04-02 | Givaudan Corporation | 2-Alkyl-3-haloisothiazolium salts and their derivatives |
-
2001
- 2001-05-10 IT IT2001MI000964A patent/ITMI20010964A1/it unknown
-
2002
- 2002-04-17 US US10/123,151 patent/US6583291B2/en not_active Expired - Fee Related
- 2002-04-17 EP EP02008612A patent/EP1258482A1/en not_active Withdrawn
- 2002-05-09 KR KR1020020025479A patent/KR100858007B1/ko not_active IP Right Cessation
- 2002-05-10 CN CNB021192413A patent/CN1199958C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ITMI20010964A1 (it) | 2002-11-10 |
EP1258482A1 (en) | 2002-11-20 |
US6583291B2 (en) | 2003-06-24 |
ITMI20010964A0 (it) | 2001-05-10 |
US20020169327A1 (en) | 2002-11-14 |
CN1385426A (zh) | 2002-12-18 |
KR100858007B1 (ko) | 2008-09-11 |
KR20020086264A (ko) | 2002-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1199958C (zh) | 获得用于头孢替坦生产的化合物的方法和由此获得的新化合物 | |
US20080223260A1 (en) | Soil-Solidifying Agent | |
KR100481326B1 (ko) | 유기태 킬레이트의 제조방법 | |
CN1332118A (zh) | 以含氟废水生产冰晶石之方法 | |
CN1197060A (zh) | 纯化支链氨基酸的方法 | |
CA2445377A1 (en) | Finely distributed stabilising composition for polymers containing halogen | |
CN1069308C (zh) | 纯化缬氨酸的方法 | |
CN1214044A (zh) | 制备4,6-二羟基嘧啶的方法 | |
GB2335187A (en) | Method of separating NaC1 from a LiC1 solution | |
KR101809145B1 (ko) | 메소-타르타르산을 포함하는 조성물의 제조방법 | |
CN1014979B (zh) | 油田用絮凝—缓蚀剂的制备方法 | |
CN1592737A (zh) | 制造西司他汀的方法 | |
CN1817869A (zh) | 工业合成取代的噻吩甲酸酯的新方法和该化合物的应用 | |
WO2004085391B1 (en) | Process for the synthesis of amorphous atorvastatin calcium | |
CN87104339A (zh) | 分离l半胱氨酸氢氯化物中-水化物的方法 | |
CN1290772C (zh) | 一种五氧化二钒的制备方法 | |
US4188493A (en) | Process for recovering CMOS | |
JPH08165271A (ja) | 2−ヒドロキシ−1,3−プロパンジアミンポリカルボン酸とそのアルカリ金属塩の製造法およびそれらを含む生分解性キレート剤 | |
RU2498989C2 (ru) | Способ получения алкиламиноалкиленфосфоновых кислот | |
DE19857690A1 (de) | Verfahren zur Isolierung oder Reinigung von 2-Methyl-thiazolidin-2,4-dicarbonsäure | |
CN1366522A (zh) | 取代的烷基胺衍生物的生产方法 | |
CA1043341A (en) | Process for preparing pyrrolidone-5,5-diphosphonic acids | |
CN116924950A (zh) | 一种2-羟基-4-取代硫基丁酸及其衍生物的制备方法 | |
JP2000301164A (ja) | ストロンチウム含有水の処理方法 | |
WO2004003099A1 (ja) | キレート剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050504 Termination date: 20140510 |